Efficacy of Tenofovir Disoproxil Fumarate in Preventing Vertical Transmission of Hepatitis B in Mothers with Chronic Hepatitis B: An Evidence-Based Case Report

Authors

  • Ris Raihan Felim Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia
  • Irsan Hasan Hepatobiliary Division, Department of Internal Medicine, Faculty of Medicine Universitas Indonesia - Cipto Mangunkusumo Hospital, Jakarta, Indonesia
  • Erni Juwita Nelwan Division of Tropical and Infectious Diseases, Department of Internal Medicine, Faculty of Medicine Universitas Indonesia - Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia.

Keywords:

Hepatitis B, Vertical transmission, Tenofovir Disoproxil Fumarate

Abstract

Background: Hepatitis B virus infection is the most common cause of chronic hepatitis. Vertical transmission is the main transmission route of this virus. Current prevention involves giving newborns immune prophylaxis within 12 hours of birth. However, there is still a failure of immunoprophylaxis, especially in cases of mothers who have a high viral load or are HBeAg positive. Tenofovir disoproxil fumarate (TDF) is the first-line treatment for chronic hepatitis B and is known to reduce perinatal HBV transmission. This study aims to determine the efficacy of TDF in preventing vertical transmission in pregnant women with chronic hepatitis B. Methods: A literature search was performed on the online databases of PubMed/MEDLINE, Embase, Scopus, Cochrane, and ScienceDirect. The inclusion criteria used were pregnant women with chronic hepatitis B and using TDF antiviral as a transmission prevention therapy with the study design used in the form of a meta-analysis, systematic review, randomized or nonrandomized controlled trial. The outcome of interest was the vertical transmission rate of hepatitis B. Results: There are two studies used with a meta-analysis study design and a nonrandomized controlled trial with a good critical review result of Validity, Importance, and Applicability. TDF significantly prevented vertical transmission of hepatitis B compared to placebo. In addition, TDF was not associated with the incidence of maternal and fetal complications. Conclusion: TDF has high effectiveness in preventing vertical transmission of hepatitis B and is safe to give to pregnant women.

References

World Health Organization. Hepatitis B [Internet]. World Health Organization. 2021 [cited 2022 Feb 11]. p. 1. Available from: https://www.who.int/news-room/fact-sheets/detail/hepatitis-b

World Health Organisation. Global progress report on HIV, viral hepatitis and sexually transmitted infections. Vol. 53. WHO: 2021 [Internet]. p. 1689–99. Available from: https://www.who.int/publications/i/item/9789240027077

Hou J, Cui F, Ding Y, et al. Management algorithm for interrupting mother-to-child transmission of hepatitis B virus. Clin Gastroenterol Hepatol. 2019;17(10):1929-36.

Watterberg K, Benitz W, Hand I, et al. Elimination of perinatal hepatitis B: Providing the first vaccine dose within 24 hours of birth. Pediatrics. 2017;140(3).

Nelson NP, Jamieson DJ, Murphy T V. Prevention of perinatal hepatitis B virus transmission. J Pediatric Infect Dis Soc. 2014;3(Suppl 1):S7.

Cheung KW, Seto MTY, Kan ASY, et al. Immunoprophylaxis failure of infants born to hepatitis B carrier mothers following routine vaccination. Clin Gastroenterol Hepatol. 2018;16(1):144–5.

Lin Y, Liu Y, Ding G, et al. Efficacy of tenofovir in preventing perinatal transmission of HBV infection in pregnant women with high viral loads. Sci Reports 2018. 2018;8(1):1–9.

Li Z, Duan X, Hu Y, et al. Efficacy and safety of lamivudine or telbivudine in preventing mother-to-child transmission of hepatitis B virus: a real-world study. Biomed Res Int. 2020;2020.

Brown RS, Mcmahon BJ, Lok ASF, et al. Antiviral therapy in chronic hepatitis B viral infection during pregnancy: a systematic review and meta-analysis. Hepatology. 2016;63(1):319–33.

Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: aasld 2018 hepatitis b guidance. Hepatology. 2018;67(4):1560–99.

Hyun MH, Lee YS, Kim JH, et al. Systematic review with meta-analysis: the efficacy and safety of tenofovir to prevent mother-to-child transmission of hepatitis B virus. Aliment Pharmacol Ther. 2017;45(12):1493–505.

Jourdain G, Ngo-Giang-Huong N, Harrison L, et al. Tenofovir versus placebo to prevent perinatal transmission of hepatitis B. N Engl J Med. 2018;378(10):911–23.

Funk AL, Lu Y, Yoshida K, et al. Efficacy and safety of antiviral prophylaxis during pregnancy to prevent mother-to-child transmission of hepatitis B virus: a systematic review and meta-analysis. Lancet Infect Dis. 2021;21(1):70–84.

Chen H, Lee C, Chang C, et al. Efficacy of maternal tenofovir disoproxil fumarate in interrupting mother‐to‐infant transmission of hepatitis B virus. Hepatology. 2015;62(2):375–86.

Mavilia MG, Wu GY. Mechanisms and prevention of vertical transmission in chronic viral hepatitis. J Clin Transl Hepatol. 2017;5(2):119.

Wong F, Pai R, Van Schalkwyk J, Yoshida EM. Hepatitis B in pregnancy: a concise review of neonatal vertical transmission and antiviral prophylaxis. Ann Hepatol. 2014;13(2):187–95.

Lin Y, Liu Y, Ding G, et al. Efficacy of tenofovir in preventing perinatal transmission of HBV infection in pregnant women with high viral loads. Sci Rep. 2018;8(1):15514.

Zeleke ED, Assefa DG, Joseph M, et al. Tenofovir disoproxil fumarate for prevention of mother-to-child transmission of hepatitis b virus: a systematic review and meta-analysis of randomised control trials. Rev Med Virol. 2021;31(5):1–16.

Downloads

Published

2024-10-25

How to Cite

Felim, R. R., Hasan, I., & Nelwan, E. J. (2024). Efficacy of Tenofovir Disoproxil Fumarate in Preventing Vertical Transmission of Hepatitis B in Mothers with Chronic Hepatitis B: An Evidence-Based Case Report. Acta Medica Indonesiana, 56(3), 411. Retrieved from https://www.actamedindones.org/index.php/ijim/article/view/2585

Issue

Vol. 56 No. 3 (2024): Acta Medica Indonesiana

Section

SPECIAL ARTICLE

License

Copyright

The authors who publish in this journal agree to the following requirements:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a  Creative Commons Attribution 4.0 International License (CC BY 4.0) that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  2. Authors can enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) before and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work. (See The Effect of Open Access)

Privacy Statement

The names and email addresses entered in this journal site will be used exclusively for the stated purposes of this journal and will not be made available for any other purpose or to any other party.